Recommendation of the President – Diaflix (dapagliflozin)
On 5 February 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 17/2026 on the reimbursement of the medicinal product Diaflix (dapagliflozin) in all registered indications as of the date of the decision: – type 2 diabetes – in adult patients and children aged 10 years and older for the treatment of inadequately controlled type 2 diabetes, as an adjunct to diet and exercise: as monotherapy when metformin is not appropriate due to intolerance; in combination with other medicinal products used to treat type 2 diabetes; – treatment of chronic kidney disease in adults; – treatment of symptomatic chronic heart failure in adults.